[1] Ata-Ali J, Zurriaga O, Alberich C. Incidence and survival rates for malignant salivary gland tumors. J Oral Sci 2016;58:67–73.
[2] Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177–84.
[3] Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004;26:681–92; discussion 692–3.
[4] Lima RA, Tavares MR, Dias FL, Kligerman J, Nascimento MF, Barbosa MM, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005;133:702–8.
[5] Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 2006;85:74
[6] Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005;63:917–28.
[7] Kaur J, Goyal S, Muzumder S, Bhasker S, Mohanti BK, Rath GK. Outcome of surgery and post-operative radiotherapy for major salivary gland carcinoma: ten year experience from a single institute. Asian Pac J Cancer Prev 2014;15:8259–63.
[8] Wahlberg P, Anderson H, Biorklund A, Moller T, Perfekt R. Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients. Oral Oncol 2002;38:706–13.
[9] Jang JY, Choi N, Ko YH, Chung MK, Son YI, Baek CH, et al. Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2 N0 high-grade salivary gland cancer. BMC Cancer 2018;18:672.
[10] Ali S, Palmer FL, Katabi N, Lee N, Shah JP, Patel SG, et al. Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 2017;127:2265–9.
[11] Qian K, Di L, Guo K, Zheng X, Ji Q, Wang Z. Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma. J Oral Maxillofac Surg 2018;76:1578–86.
[12] Yoo SH, Roh JL, Kim SO, Cho KJ, Choi SH, Nam SY, et al. Patterns and treatment of neck metastases in patients with salivary gland cancers. J Surg Oncol 2015;111:1000–6.
[13] Johnston ML, Huang SH, Waldron JN, Atenafu EG, Chan K, Cummings BJ, et al. Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head Neck 2016;38 Suppl 1:E820–6.
[14] Cerda T, Sun XS, Vignot S, Marcy PY, Baujat B, Baglin AC, et al. A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol 2014;91:142–58.
[15] Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 2001;51:952–8.
[16] North CA, Lee DJ, Piantadosi S, Zahurak M, Johns ME. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1990;18:1319–26.
[17] Pohar S, Gay H, Rosenbaum P, Klish D, Bogart J, Sagerman R, et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol Biol Phys 2005;61:112–8.
[18] Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005;61:103–11.
[19] Toonkel LM, Guha S, Foster P, Dembrow V. Radiotherapy for parotid cancer. Ann Surg Oncol 1994;1:468–72.
[20] Fitzpatrick PJ, Theriault C. Malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 1986;12:1743–7.
[21] Bhide SA, Miah A, Barbachano Y, Harrington KJ, Newbold K, Nutting CM. Radical radiotherapy for treatment of malignant parotid tumours: a single centre experience. 1995–2005. Br J Oral Maxillofac Surg 2009;47:284–9.
[22] Chen JL, Huang YS, Kuo SH, Hong RL, Ko JY, Lou PJ, et al. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma. Oncotarget 2017;8:14068–77.
[23] Hosni A, Huang SH, Goldstein D, Xu W, Chan B, Hansen A, et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol 2016;54:75–80.
[24] van der Veen J, Nuyts S. Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma? Cancers. 2017;9(10). pii: E135.
[25] Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127–36.
[26] Samant S, van den Brekel MW, Kies MS, Wan J, Robbins KT, Rosenthal DI, et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck 2012;34:1263–8.
[27] Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003;129:720–5.
[28] Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA. Stage as major long term outcome predictor in minor salivary gland carcinoma. Cancer 2000;89:1195–204.
[29] Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009;135:687–92.
[30] Maruya S, Namba A, Matsubara A, Kakehata S, Takeda I, Shirasaki T, et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol 2006;11:403–6.
[31] Hsieh CE, Lin CY, Lee LY, Yang LY, Wang CC, Wang HM, et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat Oncol 2016;11:47.
[32] Schoenfeld JD, Sher DJ, Norris CM, Jr., Haddad RI, Posner MR, Balboni TA, et al. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2012;82:308–14.
[33] Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck 2016;38:863–70.